Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Get Free Report)’s stock price dropped 1.8% during mid-day trading on Thursday. The stock traded as low as $11.43 and last traded at $11.63. Approximately 1,340,930 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 2,795,700 shares. The stock had previously closed at $11.84.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on CMPS shares. Wolfe Research reiterated an “outperform” rating on shares of Compass Pathways in a report on Tuesday, July 7th. Stifel Nicolaus raised their price objective on shares of Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Morgan Stanley lifted their price target on shares of Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Evercore raised Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price on the stock in a research report on Wednesday, July 8th. Finally, Royal Bank Of Canada dropped their price target on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.36.
Check Out Our Latest Report on CMPS
Compass Pathways Stock Performance
The firm has a market capitalization of $1.61 billion, a PE ratio of -2.52 and a beta of 2.55. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The firm’s fifty day moving average price is $13.15 and its 200 day moving average price is $11.87.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). On average, research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.26 earnings per share for the current year.
Hedge Funds Weigh In On Compass Pathways
Several large investors have recently bought and sold shares of the stock. Vivo Capital LLC acquired a new stake in Compass Pathways during the first quarter valued at approximately $1,106,000. Seven Fleet Capital Management LP increased its position in shares of Compass Pathways by 295.1% during the 1st quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock worth $874,000 after purchasing an additional 118,021 shares in the last quarter. Orbimed Advisors LLC acquired a new position in Compass Pathways in the first quarter valued at about $6,363,000. Eversept Partners LP acquired a new stake in shares of Compass Pathways during the first quarter worth approximately $3,749,000. Finally, Eagle Health Investments LP boosted its holdings in shares of Compass Pathways by 35.6% in the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock worth $11,394,000 after acquiring an additional 541,039 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.
Compass Pathways Company Profile
Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.
Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.
Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.
Read More
- Five stocks we like better than Compass Pathways
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}